PATENT UMD 1-037CIP

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SEP 1 1 2000

Group Art Unit: 1653

Examiner: Devesh Srivastava

In Re Patent Application Of: Kirin K. Chada et al.

Serial No.: 08/852,666

Filed: 7 May 1997

For: HMGI PROTEINS IN CANCER AND OBESITY

Honorable Commissioner of Patents and Trademarks

Washington, D.C. 20231

## AMENDMENT AND RESPONSE PURSUANT TO 37 C.F.R. SECTION 1.111

Sir:

This Amendment and Response pursuant to 37 C.F.R. Section 1.111 is in reply to the Examiner's Action dated 28 October 1999 in the above-identified patent application in which claims 1-40 are pending, claims 1-5, 13-15, 20-22, 26-28, and 33-40 have been withdrawn subject to a restriction requirement, and claims 6-12, 16-19, 23-25 and 29-32 were rejected. A Response to this Action was originally due 23 May 2000. Applicants have petitioned, pursuant to 37 C.F.R. Section 1.136(a), concurrently herewith for a one (1) month extension to extend the time for response to the Examiner's Action dated 23 May 2000 for one

## CERTIFICATE OF MAILING PURSUANT TO 37 C.F.R. SECTION 1.8

Muca

Richard R. Muccino

Reg. No. 32,538

Attorney for Applicant(s)

Kirin K. Chada et al. Serial No. 08/852,666 Filing Date 7 May 1997 Page 2

month from 23 August 2000 up to and including 23 September 2000 and have paid the required fee pursuant to 37 C.F.R. Sections 1.136(a) and 1.17. Applicants have also filed concurrently herewith a request for a patent application filing pursuant to the continuing prosecution application procedure in accord with 37 C.F.R. Section 1.53(d). Accordingly, this Response is timely filed.

Applicant requests that the Examiner consider the following Response and pass the above-identified application to issue.

Kindly amend the subject application as follows.

## IN THE CLAIMS

Kindly amend the claims as follows. Please cancel claims 6-12,

16-19, 23-25 and 29-32 and add claims 33-38, as set out below.

33. A method for screening candidate compounds capable of inhibiting HMGI biological activity which comprises the steps of:

- (a) immobilizing a HMGI protein or a fragment thereof on a solid surface;
- (b) incubating the HMGI protein with a candidate compound under conditions which promote optimal interaction; and
- (c) measuring the binding affinity of the candidate compound to the HMGI protein or a fragment whereof; and
- (d) determining from the binding affinity which candidate compounds inhibit the HMGI biological activity.

121